Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Islet Transplantation in Diabetes Mellitus Type 1 Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Pancreatitis, Insulin Dependent Diabetes
Interventions: Hydroxychloroquine, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet Cell Transplantation; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Kidney Transplantation
Interventions: Belatacept; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Type 1 Diabetes, Severe Hypoglycemic Unawareness
Interventions: Islet Cell Transplant; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1
Interventions: Islets of Langerhans; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Diabetes Mellitus, Type 1
Interventions: Allogeneic Cultured Islet Cells (human); Encapsulated; Biological
Lead sponsor: Novocell; Industry
Eligibility: 20 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Islet Transplantation, Type1 Diabetes Mellitus
Interventions: Continuous Glucose Monitor (CGM); Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus, Tacrolimus, Etanercept, Islet Transplantation, Basiliximab; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 7
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 3 more

Conditions: Diabetes Mellitus, Type 1
Interventions: islet cell transplantation; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus
Interventions: Islet Transplantation, Islet cell transplantation; Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Islets of Langerhans transplantation; Biological
Lead sponsor: CellTrans Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 1
Interventions: Transplantation of Human Islets; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Type 1
Interventions: Allogenic Islet Cell Transplantation; Biological
Lead sponsor: Kenneth Brayman, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus, Type 1
Interventions: Islet Cell Transplantation; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: Donislecel (allogeneic islets of Langerhans for transplant); Biological
Lead sponsor: CellTrans Inc.; Industry
Eligibility: 18 Years to 75 Years
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus, Hypoglycemia
Interventions: Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus, anti-thymocyte globulin; Biological · Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus, Type 1
Interventions: Islet Cell Transplant, Islet Cell Transplant plus; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus, Hypoglycemia
Interventions: Allogeneic Islets of Langerhans; Biological
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets; Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 68 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 9
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Diabetes Mellitus, Type I
Interventions: islets; Drug
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogeneic Pancreatic Islet Cells, Antithymocyte globulin, Daclizumab, Rituximab, Sirolimus; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus
Interventions: Islet Transplantation + Immunosuppression, Islet cell transplantation; Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2026
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

LEA29Y (Belatacept) Emory Edmonton Protocol

Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT

Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen

Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients

A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus

Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients

CGM Use in Islet Transplant Recipients

Islet Transplantation in Type 1 Diabetes

Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression

Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression

Islet Transplant in Patients With Type I Diabetes

Islet Cell Transplants for Diabetes

Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

MGA031, Sirolimus and Tacrolimus in Islet Transplantation

Efficacy of Islet After Kidney Transplantation

Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression

B-Lymphocyte Immunotherapy in Islet Transplantation

Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen